How to Read an IPO DRHP: A Retail Investor's 12-Point Prospectus Checklist

A Draft Red Herring Prospectus (DRHP) is the document an Indian company files with SEBI before an IPO, and its structure is heavily standardised under the ICDR Regulations. With a 30-to-60-minute window, you can extract most of what matters by working through 12 checkpoints in a deliberate order: issue structure, objects of the issue, risk factors, business model, promoter holding, related parties, litigation, restated financials, capital-efficiency ratios, peer valuation, management quality, and recent fundraising. The DRHP is not built to be read cover to cover; it is built to be searched, and this checklist is the search query. 

The following sections walk through all 12 checkpoints and explain what each one reveals about an IPO before you decide whether to apply.

#How to Use The Checklist

Read the DRHP in the order below, not the order it is printed. The cover-page summary and the Basis for Issue Price come early; the risk factors are buried under marketing-friendly business descriptions; the financial statements sit at the back. This checklist follows the order an investor benefits from, not the document's layout.

For each item, note three things only: what the section reveals, whether the disclosure looks healthy or concerning, and what action to take if the concern is material enough to affect your decision. That action step is what most retail readings miss; without it, the exercise becomes information collection rather than decision support.

#Issue and Proceeds Checks

#1. Issue Structure: Fresh Issue vs Offer for Sale

Check how much of the IPO is a fresh issue versus an Offer for Sale (OFS), and what happens to post-issue promoter holding. Find it in "The Issue" and "Capital Structure." Healthy: a meaningful fresh issue with promoters retaining a meaningful post-issue stake. Red flags: OFS-heavy issues where most proceeds exit to existing holders. Treat an OFS-heavy issue as a liquidity event for prior backers and apply a more conservative valuation.

#2. Objects of the Issue

Check how fresh-issue proceeds will be used. Find it in "Objects of the Issue" or "Use of Proceeds." Healthy: specific, measurable uses tied to amounts and timelines. Red flags: heavy reliance on "general corporate purposes," or shifting use-of-proceeds language between the DRHP and RHP. If proceeds don't clearly improve growth or solvency, value the issue more conservatively.

#3. Risk Factor Specificity and Internal Consistency

Check the top-ranked risks, whether they are quantified and issuer-specific. Find them in "Risk Factors," after the summary. Healthy: material risks clearly prioritised and cross-referenced. Red flags: boilerplate risk language, missing quantification, or a serious issue that looks small in risk factors but large elsewhere. Treat weak risk disclosure as a governance warning.

#Business and Governance Checks

#1. Business Model and Revenue Dependency

Check how the company makes money and whether revenue leans heavily on a few customers, suppliers, or geographies. Find it in "Industry Overview" and "Our Business." Healthy: clear revenue drivers and realistic market claims backed by independent sources. Red flags: overdependence on a few counterparties, unsupported "market leader" claims, or business complexity management can't explain crisply. Demand a stronger margin of safety where dependency is high.

#2. Promoter Holding, History, and Pledges

Check promoter background, pre- and post-issue holdings, lock-ins, and whether shares are pledged. Find it in "Capital Structure" and "Our Promoters and Promoter Group." Healthy: meaningful promoter ownership after listing, no material governance labels. Red flags: low or sharply reduced promoter commitment, disclosed encumbrances, or adverse regulatory histories. Avoid premium valuations where promoter alignment looks weak.

#3. Related-Party Transactions

Check the volume, nature, and trend of related-party sales, purchases, loans, and guarantees. Find them in "Related Party Transactions," "Group Companies," and financial notes. Healthy: transparent disclosure with transactions explained commercially. Red flags: a large share of revenue or purchases from related parties, or disclosures that overstate independence from the promoter group. Treat heavy related-party dependence as both a business-quality and governance risk.

#4. Litigation and Contingent Liabilities

Check material civil, criminal, tax, and regulatory cases involving the company, promoters, and key management, and compare contingent liabilities with net worth. Find them in "Outstanding Litigation and Material Developments" and financial notes. Healthy: clear materiality thresholds and modest contingent liabilities. Red flags: ongoing disputes with large potential outflows, or contingent liabilities big enough to erode net worth. Mentally haircut equity value by the probability-weighted potential outflow.

#Financial and Valuation Checks

#1. Financial Track Record and Auditor's Report

Check the restated financial statements, auditor's report, accounting policies, cash-flow statement, and notes for qualifications, emphasis of matter, or unusual adjustments. Find them in "Restated Financial Statements" or "Financial Information." Healthy: stable or improving revenue and profit, operating cash flow that broadly supports profit over time, and no serious audit qualifications. Red flags: audit qualifications, repeated negative operating cash flow despite reported profits, or restated figures that need heavy reconciliation. Don't rely on headline profit growth if the cash flow and audit language suggest weak earnings quality.

#2. RoE, RoCE, Leverage, and Working-Capital Cycle

Check RoE or RoNW, RoCE, debt-equity, EPS, NAV, and receivable, inventory, and payable days. Find them in the "Basis for Issue Price" and the key financial ratio sections. Healthy: stable or improving returns, manageable leverage, and a working-capital cycle appropriate for the industry. Red flags: declining returns, rising leverage, or stretched receivables and inventory without a credible explanation. Treat poor capital efficiency as a sign that growth quality is lower than the headline story suggests.

#3. Basis for Issue Price and Peer Valuation

Check the issuer's P/E, P/B and EPS against listed peers in the "Basis for Issue Price" section, the most carefully written part of the DRHP, precisely because the issuer wants you to anchor on it. Healthy: a genuinely comparable peer set, clearly defined metrics, and a valuation explainable by profitability, growth, and balance-sheet quality. Red flags: cherry-picked peers, premium pricing over higher-quality listed comparables, or a steep valuation step-up from recent transactions without matching fundamentals. Recalculate the peer comparison using the DRHP's own data and resist pricing built on narrative rather than numbers.

#4. Management Quality and Approvals

Check directors, key management, board committees, independence, experience, and the status of key government and regulatory approvals. Find them in "Our Management," "Corporate Governance," and "Government and Other Approvals." Healthy: relevant independent directors, functional governance committees, and all material approvals in place. Red flags: pending key approvals, repeated penalties or filing lapses, or a board weak relative to business complexity. Assume higher execution risk and stay conservative, especially where the company also seeks premium pricing.

#5. Recent Fundraising and Valuation Step-Up

Check the history of equity issuances, ESOPs, pre-IPO placements, and recent secondary sales, and compare pricing with the IPO valuation. Find it in "Capital Structure" and "Basis for Issue Price," especially issues and transfers in the 18 months before filing. Healthy: a coherent valuation build-up supported by improving fundamentals, with no obvious misalignment between pre-IPO investors and public shareholders. Red flags: recent rounds at much lower prices, complex instruments, or large valuation jumps unsupported by business improvement. Pay particular attention to equity issuances, ESOPs, pre-IPO placements and recent secondary transactions, and compare their pricing with the proposed IPO valuation. 

#Heuristics and What the Checklist Cannot Tell You

An OFS-heavy issue, disclosed promoter pledges, high related-party revenue concentration, contingent liabilities large relative to net worth, audit qualifications, or active tax and regulatory litigation all justify deeper caution, even where the DRHP is technically compliant.

On valuation, cross-check whether the peer group is genuinely comparable, whether return ratios are rising because of business improvement rather than one-offs, whether the working-capital cycle is worsening, and whether the IPO price implies a sharp step-up from recent rounds. A useful discipline is to write your 12 answers into a one-page note before reading any third-party analyst report; anchoring on someone else's framing first tends to lock in errors that are hard to undo.

The DRHP is a disclosure document, not a recommendation. It tells you what the issuer is required to say, not whether the business will do well, whether the price is right, or whether the macro backdrop will support the listing. Three caveats matter most:

1. KPI definitions vary across issuers; two companies in the same industry can define "active users" or "addressable market" differently.
2. Related-party disclosure is tightening through newer SEBI standards, but depth still varies.
3. Litigation materiality thresholds are set company by company, so similar legal risk can appear in different depths and formats.

Investments in securities markets are subject to market risks. Read all the related documents carefully before investing.

#Conclusion

Reading a DRHP well doesn't mean reading every page; it means asking 12 focused questions in the right order and, for each, deciding what the answer means for your subscription call. Work through issue structure, governance, and valuation deliberately, write your own one-page verdict before you look at anyone else's, and let the red flags- OFS-heavy issues, weak promoter alignment, stretched valuations- set the level of caution. The checklist makes you a faster, more disciplined reader, but it doesn't replace judgment on price, macro, and your own risk tolerance. 

Open a Demat account and use this checklist to evaluate upcoming IPOs with greater confidence.